2024-512999-35-00招募中2 期
LOGICAN : Randomised phase II study evaluating trifluridine/tipiracil plus oxaliplatin ± nivolumab versus FOLFOX ± nivolumab in patients with HER2 negative locally advanced, recurrent or metastatic gastric, oesophageal or junctional adenocarcinoma
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- Unicancer
- 入组人数
- 118
- 试验地点
- 31
- 主要终点
- PFS defined as the time from the date of randomisation to date of disease progression (radiological or clinical) or death from any cause, whichever occurs first. Patients without tumour progression or death at the time of analysis will be censored at the date of their last tumour assessment.
研究概览
简要总结
The primary objective is to evaluate the superiority of trifluridine/tipiracil + oxaliplatin ± nivolumab over FOLFOX regimen ± nivolumab in terms of Progression-Free Survival (PFS), in first-line palliative setting, in patients with HER 2 negative locally advanced, recurrent or metastatic gastric, oesophagus or gastroesophageal junction adenocarcinoma.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 是
入选标准
- •Histologically confirmed locally advanced, recurrent or metastatic non resectable adenocarcinoma of the stomach, oesophagus or gastroesophageal junction (GEJ) ineligible to curative treatment.
- •Women of childbearing potential must have a negative serum or urine pregnancy test done within 14 days before the first study treatment.
- •Patients must agree to use adequate contraception methods for the duration of study treatment and within 6 months after completing treatment.
- •Patients must be affiliated to a Social Security System (or equivalent).
- •Patient must have signed and dated a written informed consent form prior to any trial specific procedures. When the patient is physically unable to give their written consent, a trusted person of their choice, independent from the investigator or the sponsor, can confirm in writing the patient’s consent.
- •Availability of archived tumour material for ancillary studies
- •No dysphagia or difficulty in swallowing.
- •No overexpression/amplification of HER2 (IHC 0 or 1+; if IHC is 2+, HIS must be negative). Known CPS PD-L1 score (result in % with the name of the method used). The microsatellite and MMR status of patient’s tumour (MSI/MSS and pMMR/dMMR) must also be known at the time of screening (IHC and PCR tests have to be done).
- •At least one evaluable lesion according to RECIST v1.1 outside any previously irradiated area.
- •No prior palliative chemotherapy.
- •Age ≥18 years old.
- •Patient eligible for FOLFOX chemotherapy
- •Adequate organs function: - Absolute neutrophils count ≥1.5x109/L - Platelets count ≥100x109/L - Haemoglobin ≥9 g/L - Serum bilirubin levels <2 times upper limit of normal (ULN), up to 2.5 times ULN in case of hepatic metastasis (biliary drainage allowed) - Transaminases <5 times ULN - Creatinine clearance >40 mL/min
- •No Dihydropyrimidine dehydrogenase (DPD) deficiency (uracilemia <16 ng/ml)
排除标准
- •Patient with a performance status ECOG PS >
- •Interstitial lung disease.
- •Prior pneumonitis requiring systemic corticosteroid therapy.
- •Active infections.
- •Pregnant or breastfeeding woman.
- •Participation in another therapeutic trial within the 30 days prior to randomisation.
- •Persons deprived of their liberty or under protective custody or guardianship.
- •Clinically relevant coronary artery disease or history of myocardial infarction in the last 12 months, or high risk of uncontrolled arrhythmia (for men: QTc ≥450 msec, for women: QTc ≥470 msec)
- •Active systemic autoimmune disease. Subjects with vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enrol.
- •Subjects with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days prior to first study drug administration. Inhaled or topical steroids are permitted in the absence of active autoimmune disease
- •History of anterior organ transplant, including stem cell allograft
- •Other current or previous malignancy within the past 3 years (with the exception of squamous cell carcinoma of the skin treated by surgery).
- •Adjuvant chemotherapy, adjuvant immunotherapy or radio-chemotherapy completed for less than 6 months.
- •Peripheral neuropathy of NCI-CTCAE grade ≥2 at baseline.
- •Patients with known allergy or severe hypersensitivity to any of the trial drugs or any of the trial drug excipients.
- •Patients unwilling or unable to comply with trial obligations for geographic, social, or physical reasons, or who are unable to understand the purpose and procedures of the trial.
- •Previous treatment with trifluridine/tipiracil.
- •Known Human Immunodeficiency Virus (HIV) infection.
- •Active Hepatitis B virus (HBV, defined as having a positive hepatitis B surface antigen [HBsAg] test prior to inclusion) or hepatitis C virus (HCV).
结局指标
主要结局
PFS defined as the time from the date of randomisation to date of disease progression (radiological or clinical) or death from any cause, whichever occurs first. Patients without tumour progression or death at the time of analysis will be censored at the date of their last tumour assessment.
PFS defined as the time from the date of randomisation to date of disease progression (radiological or clinical) or death from any cause, whichever occurs first. Patients without tumour progression or death at the time of analysis will be censored at the date of their last tumour assessment.
次要结局
- Efficacy endpoints:ORR (according to RECIST v1.1) defined as the percentage of patients with Complete Response (CR) or Partial Response (PR). Patients who discontinue treatment without a tumour assessment will be considered non-responders for the analysis
- Efficacy endpoints : Overall survival (OS), defined as the time from date of randomisation to the date of death from any cause. Patients alive at the database cut-off date will be censored at the last date of follow-up.
- Safety and tolerability of treatment (NCI-CTCAE version 5.0) determined through the incidence of adverse events, treatment related adverse events, serious adverse Events (SAE), and death.
- Time to PS deterioration >2 defined as the time between patient randomisation and the first date when PS>2
- Quality of Life (QoL) according to QLQ-C30 questionnaire
研究者
Nourredine AIT RAHMOUNE
Scientific
Unicancer
研究点 (31)
Loading locations...
相似试验
招募中
2 期
Phase II study of FTD/TPI plus RAM compared with FTD/TPI for advanced gastric cancer (WJOG15822G)JPRN-jRCTs041220120Hiroki Hara110
已完成
2 期
A phase 2 study of trifluridine/tipiracil in patients with ER-positive, HER2-negative advanced breast cancer that previously received chemotherapyER-positive breast cancerHer2 negative10006291Metastatic breast cancerNL-OMON52884BOOG Study Center50
进行中（未招募）
2 期
TAS102 in patients with ER-positive, HER2-negative advanced breast cancer (TIBET study)Advanced breast cancer2024-519204-27-00BOOG Study Center B.V.50
尚未招募
2 期
Single-arm, phase II trial of trifluridine/tipiracil (FTD-TPI), bevacizumab, and individualized radioembolization with 166Ho-microspheres in refractory metastatic colorectal cancer.colorectal cancerNL-OMON56792niversitair Medisch Centrum Utrecht40
已完成
2 期
Phase 2/3 study of fluoropyrimidine and irinotecan plus bevacizumab versus trifluridine/tipiracil plus bevacizumab as second-line for metastatic colorectal cancer (TRUSTY)JPRN-jRCT1080223562Taiho Pharmaceutical Co., Ltd.524